Eunomia perspective · 2026-06-02 · ABPI Code & PMCPA, Regulatory Updates & Compliance News

PMCPA’s 2026 Social Media Guidance: Compliance Priorities Companies Should Address Now

Published by Eunomia Pharma Services · Updated 29 September 2026

What does the PMCPA’s 2026 social media guidance mean for pharmaceutical companies?

The PMCPA’s updated guidance reinforces that compliance obligations under the ABPI Code do not diminish online. Companies need clear governance for employee activity, corporate accounts, influencer and third-party collaborations, user-generated content and adverse event monitoring, supported by policies, training, monitoring and documentation.

Where to start

Review your social media policy against the updated PMCPA guidance.
Brief employees on what they can share, like or comment on about company products.
Put influencer and agency content through the same review and certification route as other materials.
Make sure adverse events spotted on social media are recognised and reported.

The practical steps above are Eunomia’s operational guidance. See the source notes below for the scope of the external references.

Key Takeaways

The PMCPA’s 2026 Social Media Guidance reflects the increasing role of digital channels in pharmaceutical communications.
Companies are expected to maintain the same compliance standards online as they do across traditional communication channels.
Employee activity, corporate social media accounts, influencer collaborations, and user-generated content require clear governance and oversight.
Effective social media compliance requires a combination of policies, training, monitoring, and documentation.
Organisations that strengthen their digital compliance frameworks now will be better positioned to manage future regulatory expectations.

Social Media Compliance Is No Longer a Secondary Consideration

Digital communication continues to transform how pharmaceutical companies engage with healthcare professionals, patient communities, employees, and the wider public.

Social media platforms offer valuable opportunities for education, awareness, scientific exchange, and corporate communication. However, they also introduce unique compliance challenges that can develop quickly and spread widely if not appropriately managed.

Recognising these evolving risks, the Prescription Medicines Code of Practice Authority (PMCPA) has updated its Social Media Guidance for 2026, providing greater clarity on how the ABPI Code applies within digital environments.

While many of the underlying principles remain unchanged, the guidance reinforces an important message: compliance obligations do not diminish simply because communication takes place online.

For pharmaceutical companies, now is an appropriate time to review existing governance frameworks and identify areas where additional controls may be required.

Why Social Media Continues to Present Compliance Challenges

Unlike traditional promotional materials, social media content is often created, shared, commented on, and redistributed rapidly across multiple audiences. The distinction between corporate communication, personal opinion, promotional messaging, and scientific exchange can sometimes become blurred.

This creates challenges in areas such as:

Promotion of prescription-only medicines.
Engagement with healthcare professionals.
Management of employee social media activity.
Adverse event identification and reporting.
Transparency and disclosure obligations.
Third-party and influencer relationships.
User-generated content and public comments.

Employee Activity Remains a Key Area of Focus

One of the most important themes reinforced within the updated guidance is the role employees play in representing their organisations online.

Employees may use social media for professional networking, industry discussions, conference participation, recruitment, or sharing company achievements. While these activities can provide significant business value, they can also create regulatory exposure if appropriate guardrails are not in place.

For example, employees may inadvertently:

Share information that could be interpreted as promotional.
Discuss unapproved products or indications.
Engage in public discussions with healthcare professionals or patients.
Amplify corporate content without understanding associated compliance considerations.

Governance of Corporate Social Media Channels

Corporate social media accounts often serve as highly visible extensions of an organisation's public presence.

The PMCPA guidance reinforces the importance of maintaining robust oversight of content published through official channels.

This includes ensuring that:

Content review and approval processes are clearly documented.
Responsibilities for account management are defined.
Promotional and non-promotional communications are appropriately distinguished.
Records of published content are retained where required.
Monitoring processes are in place for comments and interactions.

Third Parties, Influencers, and External Content Require Oversight

As companies increasingly collaborate with external stakeholders, the boundaries of organisational responsibility can become less clear.

The updated guidance highlights the need for appropriate oversight when engaging third parties who may communicate on behalf of, or in association with, pharmaceutical organisations.

This may include:

Healthcare professionals participating in awareness campaigns.
Patient advocates.
Disease awareness ambassadors.
Digital content creators and influencers.
External agencies managing social media activity.

Even where content is created externally, organisations may still carry responsibility for ensuring communications comply with applicable requirements.

Clear contractual obligations, training expectations, review processes, and monitoring arrangements can help reduce risk while supporting effective collaboration.

Adverse Event Monitoring Remains Critical

Social media channels may serve as a source of safety information, including adverse event reports and product complaints.

Companies should ensure that employees responsible for managing digital channels understand how potential safety information should be identified, documented, and escalated.

Processes should be aligned with existing pharmacovigilance procedures and supported by appropriate training.

As digital engagement expands, organisations should periodically assess whether current monitoring practices remain effective and proportionate to their social media footprint.

Preparing for Future Expectations

The PMCPA's updated guidance should not be viewed solely as a regulatory requirement.

It also provides an opportunity for organisations to evaluate whether their digital governance frameworks remain fit for purpose.

Practical actions companies may consider include:

Reviewing social media policies and procedures.
Updating employee training programs.
Assessing approval workflows for digital content.
Evaluating monitoring and record-retention processes.
Reviewing third-party governance frameworks.
Testing adverse event escalation procedures.
Conducting periodic social media compliance risk assessments.

These activities can help organisations build confidence that digital communications are supported by appropriate controls while continuing to enable meaningful stakeholder engagement.

How Eunomia Pharma Services Can Help

At Eunomia Pharma Services, we support pharmaceutical, biotech, and healthcare organisations in navigating evolving compliance expectations across both traditional and digital channels.

Our services include social media compliance assessments, policy development, employee training, governance framework design, third-party oversight support, and operational compliance advisory services.

As regulatory expectations surrounding digital engagement continue to evolve, organisations benefit from compliance frameworks that are practical, scalable, and aligned with business objectives.

Our goal is to help companies engage confidently within digital environments while maintaining compliance with applicable industry standards.

Frequently Asked Questions

What is the PMCPA Social Media Guidance?

The PMCPA Social Media Guidance provides practical direction on how the ABPI Code of Practice applies to social media communications and digital engagement activities.

Does the guidance apply to employee personal social media accounts?

Yes. Employee activity can create compliance risk where individuals are identifiable as company representatives or discuss company-related matters.

Are pharmaceutical companies responsible for content created by third parties?

In many circumstances, companies may retain responsibility for content that they sponsor, commission, approve, or otherwise influence.

Why is social media monitoring important?

Monitoring helps organisations identify potential compliance issues, adverse event reports, product complaints, and inappropriate interactions that may require action.

Building a Sustainable Digital Compliance Framework

Social media is now an established component of pharmaceutical communications, stakeholder engagement, and corporate reputation management.

The PMCPA's 2026 Social Media Guidance reinforces that compliance expectations apply equally across digital and traditional channels.

Organisations that proactively strengthen governance, training, monitoring, and oversight today will be better positioned to manage evolving regulatory expectations tomorrow.

To learn how Eunomia Pharma Services can support your organisation's social media compliance strategy, contact our team to start the conversation.

Sources and scope

PMCPA: Social media guidance
The PMCPA’s guidance on applying the ABPI Code to social media, updated in February 2026.
PMCPA: 2024 ABPI Code of Practice
The UK industry code, in effect from 1 October 2024 and administered by the PMCPA independently of the ABPI.

External sources accessed 29 September 2026. Check the applicable country rules and current source text for a specific engagement.